Cargando…

Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome

PURPOSE: Cytomegalovirus (CMV) reactivation occurs frequently in patients with the acute respiratory distress syndrome (ARDS) and has been associated with increased mortality. However, it remains unknown whether this association represents an independent risk for poor outcome. We aimed to estimate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ong, David S. Y., Spitoni, Cristian, Klein Klouwenberg, Peter M. C., Verduyn Lunel, Frans M., Frencken, Jos F., Schultz, Marcus J., van der Poll, Tom, Kesecioglu, Jozef, Bonten, Marc J. M., Cremer, Olaf L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747999/
https://www.ncbi.nlm.nih.gov/pubmed/26415682
http://dx.doi.org/10.1007/s00134-015-4071-z
_version_ 1782415045173444608
author Ong, David S. Y.
Spitoni, Cristian
Klein Klouwenberg, Peter M. C.
Verduyn Lunel, Frans M.
Frencken, Jos F.
Schultz, Marcus J.
van der Poll, Tom
Kesecioglu, Jozef
Bonten, Marc J. M.
Cremer, Olaf L.
author_facet Ong, David S. Y.
Spitoni, Cristian
Klein Klouwenberg, Peter M. C.
Verduyn Lunel, Frans M.
Frencken, Jos F.
Schultz, Marcus J.
van der Poll, Tom
Kesecioglu, Jozef
Bonten, Marc J. M.
Cremer, Olaf L.
author_sort Ong, David S. Y.
collection PubMed
description PURPOSE: Cytomegalovirus (CMV) reactivation occurs frequently in patients with the acute respiratory distress syndrome (ARDS) and has been associated with increased mortality. However, it remains unknown whether this association represents an independent risk for poor outcome. We aimed to estimate the attributable effect of CMV reactivation on mortality in immunocompetent ARDS patients. METHODS: We prospectively studied immunocompetent ARDS patients who tested seropositive for CMV and remained mechanically ventilated beyond day 4 in two tertiary intensive care units in the Netherlands from 2011 to 2013. CMV loads were determined in plasma weekly. Competing risks Cox regression was used with CMV reactivation status as a time-dependent exposure variable. Subsequently, in sensitivity analyses we adjusted for the evolution of disease severity until onset of reactivation using marginal structural modeling. RESULTS: Of 399 ARDS patients, 271 (68 %) were CMV seropositive and reactivation occurred in 74 (27 %) of them. After adjustment for confounding and competing risks, CMV reactivation was associated with overall increased ICU mortality (adjusted subdistribution hazard ratio (SHR) 2.74, 95 % CI 1.51–4.97), which resulted from the joint action of trends toward an increased mortality rate (direct effect; cause specific hazard ratio (HR) 1.58, 95 % CI 0.86–2.90) and a reduced successful weaning rate (indirect effect; cause specific HR 0.83, 95 % CI 0.58–1.18). These associations remained in sensitivity analyses. The population-attributable fraction of ICU mortality was 23 % (95 % CI 6–41) by day 30 (risk difference 4.4, 95 % CI 1.1–7.9). CONCLUSION: CMV reactivation is independently associated with increased case fatality in immunocompetent ARDS patients who are CMV seropositive. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00134-015-4071-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4747999
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-47479992016-02-19 Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome Ong, David S. Y. Spitoni, Cristian Klein Klouwenberg, Peter M. C. Verduyn Lunel, Frans M. Frencken, Jos F. Schultz, Marcus J. van der Poll, Tom Kesecioglu, Jozef Bonten, Marc J. M. Cremer, Olaf L. Intensive Care Med Original PURPOSE: Cytomegalovirus (CMV) reactivation occurs frequently in patients with the acute respiratory distress syndrome (ARDS) and has been associated with increased mortality. However, it remains unknown whether this association represents an independent risk for poor outcome. We aimed to estimate the attributable effect of CMV reactivation on mortality in immunocompetent ARDS patients. METHODS: We prospectively studied immunocompetent ARDS patients who tested seropositive for CMV and remained mechanically ventilated beyond day 4 in two tertiary intensive care units in the Netherlands from 2011 to 2013. CMV loads were determined in plasma weekly. Competing risks Cox regression was used with CMV reactivation status as a time-dependent exposure variable. Subsequently, in sensitivity analyses we adjusted for the evolution of disease severity until onset of reactivation using marginal structural modeling. RESULTS: Of 399 ARDS patients, 271 (68 %) were CMV seropositive and reactivation occurred in 74 (27 %) of them. After adjustment for confounding and competing risks, CMV reactivation was associated with overall increased ICU mortality (adjusted subdistribution hazard ratio (SHR) 2.74, 95 % CI 1.51–4.97), which resulted from the joint action of trends toward an increased mortality rate (direct effect; cause specific hazard ratio (HR) 1.58, 95 % CI 0.86–2.90) and a reduced successful weaning rate (indirect effect; cause specific HR 0.83, 95 % CI 0.58–1.18). These associations remained in sensitivity analyses. The population-attributable fraction of ICU mortality was 23 % (95 % CI 6–41) by day 30 (risk difference 4.4, 95 % CI 1.1–7.9). CONCLUSION: CMV reactivation is independently associated with increased case fatality in immunocompetent ARDS patients who are CMV seropositive. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00134-015-4071-z) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2016-03-01 2016 /pmc/articles/PMC4747999/ /pubmed/26415682 http://dx.doi.org/10.1007/s00134-015-4071-z Text en © The Author(s) 2015 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original
Ong, David S. Y.
Spitoni, Cristian
Klein Klouwenberg, Peter M. C.
Verduyn Lunel, Frans M.
Frencken, Jos F.
Schultz, Marcus J.
van der Poll, Tom
Kesecioglu, Jozef
Bonten, Marc J. M.
Cremer, Olaf L.
Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
title Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
title_full Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
title_fullStr Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
title_full_unstemmed Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
title_short Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
title_sort cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
topic Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747999/
https://www.ncbi.nlm.nih.gov/pubmed/26415682
http://dx.doi.org/10.1007/s00134-015-4071-z
work_keys_str_mv AT ongdavidsy cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome
AT spitonicristian cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome
AT kleinklouwenbergpetermc cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome
AT verduynlunelfransm cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome
AT frenckenjosf cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome
AT schultzmarcusj cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome
AT vanderpolltom cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome
AT kesecioglujozef cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome
AT bontenmarcjm cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome
AT cremerolafl cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome